FDA Clears Meridian Illumigene Pertussis Test | GenomeWeb

NEW YORK (GenomeWeb News) — Meridian Bioscience said today that it has received US Food and Drug Administration clearance for its Illumigene Bordetella pertussis molecular diagnostic test.

The Illumigene Pertussis test is the fifth assay on Meridian's Illumigene platform, which is based on loop-mediated isothermal amplification. The test amplifies a specific DNA target to detect B. pertussis, providing a definitive result and helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.